Zobrazeno 1 - 10
of 589
pro vyhledávání: '"Wei Yu"'
Autor:
Huakun Lv, Shenyu Wang, Zhenzhen Liang, Wei Yu, Chuanfu Yan, Yingping Chen, Xiaosong Hu, Rong Fu, Minghuan Zheng, Thomas Group, Alain Luxembourg, Xueyan Liao, Zhiping Chen
Publikováno v:
Vaccine. 40:3263-3271
The 9-valent human papillomavirus (9vHPV; HPV6/11/16/18/31/33/45/52/58) vaccine was approved for use in Chinese women aged 16-26 years in 2018. This phase 3, open-label study (NCT03903562) compared 9vHPV vaccine immunogenicity and safety in Chinese f
Autor:
Yi Hong Liu, Ying Tsen Chou, Fu Pang Chang, Wei Ju Lee, Yuh Cherng Guo, Cheng Ta Chou, Hui Chun Huang, Takeshi Mizuguchi, Chien Chen Chou, Hsiang Yu Yu, Kai Wei Yu, Hsiu Mei Wu, Pei Chien Tsai, Naomichi Matsumoto, Yi Chung Lee, Yi Chu Liao
Publikováno v:
Brain. 145:3010-3021
Neuronal intranuclear inclusion disease (NIID), caused by an expansion of GGC repeats in the 5′-untranslated region of NOTCH2NLC, is an important but underdiagnosed cause of adult-onset leukoencephalopathies. The present study aimed to investigate
Autor:
Zhong-You, Zeng, Hong-Fei, Wu, Shi-Yang, Fan, Sun-Wu, Fan, Xiang-Qian, Fang, Xing, Zhao, Yong-Xing, Song, Wei, Yu, Fei, Pei, Guo-Hao, Song
Publikováno v:
Zhongguo gu shang = China journal of orthopaedics and traumatology. 35(10)
To summarize and compare the endplate injury occurrence characteristics and clinical results of transforaminal intervertebral fusion combined with pedicle screw fixation through intermuscular approach and oblique lateral intervertebral fusion combine
Autor:
Tom Wei-Wu Chen, Chia-Lang Hsu, Ruey-Long Hong, Jen-Chieh Lee, Koping Chang, Chih-Wei Yu, San-Chi Chen, Jhe-Cyuan Guo, Mei-Lu Chen, Meng-Chi Hsu, Ting-Fang Kung, Ann-Lii Cheng, Chueh-Chuan Yen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(23)
Purpose: Satisfactory treatment options for advanced leiomyosarcoma and liposarcoma are limited. The LEADER study (NCT03526679) investigated the safety and efficacy of lenvatinib plus eribulin. Patients and Methods: LEADER is a multicenter phase Ib/I
Autor:
Yang Yang, Jindong Sheng, Shuai Hu, Yun Cui, Jing Xiao, Wei Yu, Jing Peng, Wenke Han, Qun He, Yu Fan, Yuanjie Niu, Jun Lin, Ye Tian, Chawnshang Chang, Shuyuan Yeh, Jie Jin
Publikováno v:
Cell Death & Disease. 13
Benign prostatic hyperplasia (BPH) is the most common and progressive urological disease in elderly men worldwide. Epidemiological studies have suggested that the speed of disease progression varies among individuals, while the pathophysiological mec
Publikováno v:
Clinical Endocrinology. 94:765-773
OBJECTIVE Patients with 21-hydroxylase deficiency (21-OHD) are at risk of reduced bone mineral density (BMD) and fracture due to long-term glucocorticoid treatment. Trabecular bone score (TBS) is complementary to conventional BMD as a marker for bone
Publikováno v:
Journal of Alzheimer's Disease. 77:367-374
Background: Diabetes may increase the risk of conversion of mild cognitive impairment (MCI) to dementia. Lipid accumulation product (LAP), an index of visceral obesity, has been shown to be a powerful predictor of insulin resistance and type 2 diabet
Autor:
Jianping Xiong, Wei-Yu Xu, Xuezhu Wang, Zhongtao Zhang, Yongchang Zheng, Xiaoqian Wu, Si Yu, Xinting Sang
Publikováno v:
Aging (Albany NY)
Although KIAA0101 is involved in many diseases, its expression and prognostic value in HCC remain undefined. According to CCLE, KIAA0101 is highly expressed in HCC, with a weak positive correlation between copy number and gene expression. Four studie
Autor:
Yanling Li, Fuping Guo, Taisheng Li, Wei Pan, Wenmin Guan, Xiaojing Song, Wei Yu, Evelyn Hsieh
Publikováno v:
Osteoporos Int
This is the first study to report changes in BMD and related risk factors among Chinese patients with HIV after initiation of tenofovir disoproxil fumarate (TDF)-containing antiretroviral therapy. Greater bone mineral density (BMD) loss was observed
Autor:
Yu Deng, Mark A. Socinski, Hina Patel, Geetha Shankar, Denis Moro-Sibilot, Martin Früh, Shelley Coleman, Wei Yu, Elisabeth Piault, Martin Reck, Mikhail Shtivelband, T. Wehler, José Luis González Larriba, Carlo Barone, Anthony Lee, Naoyuki Nogami, Jeffrey Rothenstein, Francisco Orlandi, Claudia Kelsch
Publikováno v:
Journal of Clinical Oncology
PURPOSE Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) demonstrated survival benefit versus bevacizumab, carboplatin, and paclitaxel (BCP) in chemotherapy-naïve nonsquamous non–small-cell lung cancer (NSCLC). We present safety and p